Dearnaley D et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047–1060

Article  PubMed  PubMed Central  Google Scholar 

Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 71:209–249

Article  Google Scholar 

Lane JA et al (2014) Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 15:1109–1118

Article  PubMed  Google Scholar 

Schaeffer E, An Y, Barocas, D, et al (2022) NCCN Guidelines Version 1.2023 Prostate Cancer. 2022. https://www.nccn.org/home/. Accessed 16 Oct 2023

Miralbell R, Roberts SA, Zubizarreta E, Hendry JH (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 14 (09–22) Gy. Int J Radiat Oncol Biol Phys 82:e17-24

Article  PubMed  Google Scholar 

Marvaso G et al (2019) Comparison of outcomes and toxicity between extreme and moderate radiation therapy hypofractionation in localized prostate cancer: a propensity score analysis. Int J Radiat Oncol Biol Phys 105:735–744

Article  CAS  PubMed  Google Scholar 

Boike TP et al (2011) Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29:2020–2026

Article  PubMed  PubMed Central  Google Scholar 

Fonteyne V et al (2012) Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. Int J Radiat Oncol Biol Phys 84:e483-490

Article  PubMed  Google Scholar 

King CR, Brooks JD, Gill H, Presti JC (2012) Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82:877–882

Article  PubMed  Google Scholar 

Hannan R et al (2016) Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer 59:142–151

Article  PubMed  Google Scholar 

Lee WR et al (2016) Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34:2325–2332

Article  ADS  PubMed  PubMed Central  Google Scholar 

Catton CN et al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35:1884–1890

Article  CAS  PubMed  Google Scholar 

Jackson WC et al (2019) Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys 104:778–789

Article  PubMed  PubMed Central  Google Scholar 

Timon G et al (2018) Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218. Br J Radiol 91:20160725

Article  PubMed  Google Scholar 

De Bari B et al (2016) Extreme hypofractionation for early prostate cancer: biology meets technology. Cancer Treat Rev 50:48–60

Article  PubMed  Google Scholar 

Tambas M et al (2016) Conventionally fractionationed volumetric arc therapy versus hypofractionated stereotactic body radiotherapy: quality of life, side effects, and prostate-specific antigen kinetics in localized prostate cancer. Value Health Reg Issues 10:91–99

Article  PubMed  Google Scholar 

Lukka HR et al (2018) Patient reported outcomes in NRG oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer. Int J Radiat Oncol Biol Phys 102:287–295

Article  PubMed  PubMed Central  Google Scholar 

Fransson P et al (2021) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol 22:235–245

Article  PubMed  Google Scholar 

Tree AC et al (2022) Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 23:1308–1320

Article  PubMed  Google Scholar 

Feutren T, Herrera FG (2018) Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review. Prostate Int 6:75–87

Article  PubMed  PubMed Central  Google Scholar 

Draulans C et al (2020) Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol 147:92–98

Article  PubMed  Google Scholar 

Cellini N et al (2002) Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 53:595–599

Article  PubMed  Google Scholar 

Pucar D et al (2007) Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 69:62–69

Article  ADS  PubMed  Google Scholar 

Ahmed HU et al (2012) Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 13:622–632

Article  PubMed  PubMed Central  Google Scholar 

Arrayeh E et al (2012) Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 82:e787-793

Article  PubMed  PubMed Central  Google Scholar 

Kerkmeijer LGW et al (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol. https://doi.org/10.1200/JCO.20.02873

Article  PubMed  Google Scholar 

Di Maio M et al (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915

Article  PubMed  Google Scholar 

Marvaso G et al (2020) Phase II prospective trial ‘Give Me Five’ short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218). Med Oncol 37:74

Article  CAS  PubMed  Google Scholar 

Timon G et al (2016) Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesion. Tumori 102:536–540

Article  PubMed  Google Scholar 

Roach M et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974

Article  PubMed  Google Scholar 

Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346

Article  CAS  PubMed  Google Scholar 

Widmark A et al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394:385–395

Article  PubMed  Google Scholar 

Di Muzio NG et al (2016) Moderate hypofractionation with simultaneous integrated boost in prostate cancer: long-term results of a phase I-II study. Clin Oncol (R Coll Radiol) 28:490–500

Article  PubMed  Google Scholar 

Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL (2003) Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer 97:1653–1662

Article  PubMed  Google Scholar 

Hyun JS (2012) Prostate cancer and sexual function. World J Mens Health 30:99–107

Article  PubMed  PubMed Central  Google Scholar 

Broughman JR et al (2018) Prostate cancer patient characteristics associated with a strong preference to preserve sexual function and receipt of active surveillance. J Natl Cancer Inst 110:420–425

Article  PubMed  Google Scholar 

ASCO GU (2023) PACE-A: An International Phase 3 Randomised Controlled Trial (RCT) Comparing Stereotactic Body Radiotherapy (SBRT) to Surgery for Localised Prostate Cancer (LPCa)—Primary Endpoint Analysis. https://www.urotoday.com/conference-highlights/asco-gu-2023/asco-gu-2023-prostate-cancer/142476-asco-gu-2023-pace-a-an-international-phase-3-randomised-controlled-trial-rct-comparing-stereotactic-body-radiotherapy-sbrt-to-surgery-for-localised-prostate-cancer-lpca-primary-endpoint-analysis.html. Accessed 16 Oct 2023

Donovan JL et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375:1425–1437

Article  CAS  PubMed  PubMed Central  Google Scholar 

Katz AJ, Kang J (2014) Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol 4:301

Article  PubMed  PubMed Central  Google Scholar